PERCHERON THERAPEUTICS LIMITED Financials Percheron Therapeutics Limited Deutsche Boerse AG
Equities
AWY0
AU0000317281
Biotechnology & Medical Research
|
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.0472 EUR | +0.64% |
|
-1.87% | +53.25% |
| 17/06 | Percheron Therapeutics Appoints CFO | MT |
| 03/06 | Percheron Therapeutics Names Chief Medical Advisor | MT |
Valuation
| Fiscal Period: June | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|
| Capitalization 1 | 36.17 | 112 | 50.16 | 39.49 | 76.63 | - | - |
| Enterprise Value (EV) 1 | 36.17 | 106.3 | 31.15 | 28.52 | 67.71 | 59.2 | 58.11 |
| P/E ratio | - | -13.1 x | - | -3.47 x | -5.42 x | -2.16 x | -3.01 x |
| Yield | - | - | - | - | - | - | - |
| Capitalization / Revenue | 46.9 x | 176 x | 27.7 x | 20.1 x | 21.3 x | 14.5 x | 21.9 x |
| EV / Revenue | 46.9 x | 167 x | 17.2 x | 14.5 x | 18.8 x | 11.2 x | 16.6 x |
| EV / EBITDA | - | -13.4 x | -5.46 x | -2.53 x | -5.14 x | -1.89 x | -2.48 x |
| EV / FCF | - | -1,81,95,824 x | -39,89,429 x | -34,86,569 x | - | - | - |
| FCF Yield | - | -0% | -0% | -0% | - | - | - |
| Price to Book | - | 19.5 x | 2.37 x | 3.96 x | 5.05 x | 2.38 x | 4.45 x |
| Nbr of stocks (in thousands) | 4,88,785 | 5,74,476 | 6,68,794 | 6,69,315 | 9,01,545 | - | - |
| Reference price 2 | 0.0740 | 0.1950 | 0.0750 | 0.0590 | 0.0850 | 0.0850 | 0.0850 |
| Announcement Date | 26/08/20 | 25/08/21 | 31/08/22 | 25/08/23 | - | - | - |
1AUD in Million2AUD
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: June | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|
| Net sales 1 | 0.7716 | 0.6368 | 1.812 | 1.965 | 3.6 | 5.3 | 3.5 |
| EBITDA 1 | - | -7.947 | -5.711 | -11.28 | -13.17 | -31.29 | -23.45 |
| EBIT 1 | - | -8.05 | -5.8 | -11.37 | -13.27 | -31.34 | -23.5 |
| Operating Margin | - | -1,264.04% | -320.07% | -578.78% | -368.53% | -591.38% | -671.43% |
| Earnings before Tax (EBT) 1 | - | -8.061 | - | -11.38 | -17.2 | -14.6 | -14.4 |
| Net income 1 | - | -8.061 | - | -11.38 | -13.08 | -31.1 | -23.27 |
| Net margin | - | -1,265.72% | - | -579.19% | -363.2% | -586.79% | -664.85% |
| EPS 2 | - | -0.0149 | - | -0.0170 | -0.0157 | -0.0394 | -0.0282 |
| Free Cash Flow | - | -5.843 | -7.809 | -8.181 | - | - | - |
| FCF margin | - | -917.42% | -430.95% | -416.37% | - | - | - |
| FCF Conversion (EBITDA) | - | - | - | - | - | - | - |
| FCF Conversion (Net income) | - | - | - | - | - | - | - |
| Dividend per Share 2 | - | - | - | - | - | - | - |
| Announcement Date | 26/08/20 | 25/08/21 | 31/08/22 | 25/08/23 | - | - | - |
1AUD in Million2AUD
Estimates
Income Statement Evolution (Quarterly data)
| Fiscal Period: June | 2021 S2 | 2024 S1 |
|---|---|---|
| Net sales 1 | - | 1.2 |
| EBITDA 1 | -6.01 | -4.693 |
| EBIT 1 | -6.01 | -4.741 |
| Operating Margin | - | -395.02% |
| Earnings before Tax (EBT) | - | - |
| Net income 1 | - | -4.743 |
| Net margin | - | -395.24% |
| EPS 2 | - | -0.006600 |
| Dividend per Share | - | - |
| Announcement Date | 25/08/21 | 28/02/24 |
1AUD in Million2AUD
Estimates
Balance Sheet Analysis
| Fiscal Period: June | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|
| Net Debt 1 | - | - | - | - | - | - | - |
| Net Cash position 1 | - | 5.71 | 19 | 11 | 8.92 | 17.4 | 18.5 |
| Leverage (Debt/EBITDA) | - | - | - | - | - | - | - |
| Free Cash Flow | - | -5.84 | -7.81 | -8.18 | - | - | - |
| ROE (net income / shareholders' equity) | - | -157% | -43.3% | - | - | - | -0.83% |
| ROA (Net income/ Total Assets) | - | - | -39.5% | - | - | - | -73.5% |
| Assets 1 | - | - | - | - | - | - | 31.66 |
| Book Value Per Share 2 | - | 0.0100 | 0.0300 | 0.0100 | 0.0200 | 0.0400 | 0.0200 |
| Cash Flow per Share 2 | - | -0.0100 | -0.0100 | -0.0100 | -0.0200 | -0.0400 | -0.0300 |
| Capex 1 | - | 0.01 | 0 | 0.03 | 0.1 | - | - |
| Capex / Sales | - | 1.31% | 0.22% | 1.49% | 2.78% | - | - |
| Announcement Date | 26/08/20 | 25/08/21 | 31/08/22 | 25/08/23 | - | - | - |
1AUD in Million2AUD
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Year-on-year evolution of the Yield
Change in Enterprise Value/EBITDA
Trading Rating
Investor Rating
ESG Refinitiv
Sell
Buy
Mean consensus
BUY
Number of Analysts
2
Last Close Price
0.085
AUD
Average target price
0.25
AUD
Spread / Average Target
+194.12%
EPS Revisions
Annual profits - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| +15.85% | 122B | |
| +18.91% | 113B | |
| +4.43% | 22.84B | |
| -18.63% | 20.72B | |
| -13.76% | 16.39B | |
| -16.61% | 16.51B | |
| -43.53% | 15.83B | |
| +1.75% | 13.49B | |
| +28.07% | 11.67B |
- Stock Market
- Equities
- PER Stock
- AWY0 Stock
- Financials Percheron Therapeutics Limited
